{
  "abstract": "The optimal long-term antithrombotic strategy for patients with atrial fibrillation (AF) and concomitant coronary artery disease (CAD) following percutaneous coronary intervention (PCI) remains a key issue in cardiovascular disease. Historically, combination therapy, comprising oral anticoagulation (OAC) with antiplatelet agents, was considered the default strategy to mitigate ischaemic events in these high-risk populations. However, the substantial bleeding risk associated with triple antithrombotic therapy (warfarin plus dual antiplatelet therapy) led to a paradigm shift to dual antithrombotic therapy (DAT) based on direct oral anticoagulants (DOACs).",
  "authors": [
    {
      "affiliations": [
        "Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea (the Republic of)",
        "Chonnam National University Medical School, Gwangju, Korea (the Republic of)"
      ],
      "name": "Joon Ho Ahn"
    },
    {
      "affiliations": [
        "Department of Cardiology, Chonnam National University Hospital, Gwangju, Korea (the Republic of)",
        "Chonnam National University Medical School, Gwangju, Korea (the Republic of)"
      ],
      "name": "Seung Hun Lee"
    }
  ],
  "title": "Underdosing in antithrombotic care: rethinking ‘less’",
  "uid": "144c6ded-ba34-505c-a3b3-de05574aab7f"
}